康辰藥業(603590.SH):續簽房屋租賃合同
格隆匯7月3日丨康辰藥業(603590.SH)公佈,公司與關聯方康辰醫藥簽訂的位於北京市昌平區生命科學園科學園路7號院4號樓的房屋租賃合同於2024年6月30日到期,為保證公司科研辦公需要,公司與康辰醫藥續簽房屋租賃合同,繼續租賃位於北京市昌平區生命科學園科學園路7號院4號樓2-5層的房屋,租賃房屋建築面積為4,015.45平方米,租賃期限三年,自2024年7月1日起至2027年6月30日止。按照4.00元/平方米/日的價格收取租金,預計年租金總額為人民幣5,862,557.00元;另外,本次續租期限內,新增車位月租賃費用為550元/個,合計13個,車位費年租金總額為人民幣85,800元。由於康辰醫藥為公司關聯方,本次交易構成關聯交易,但不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.